{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:23:45Z","timestamp":1777681425185,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Introduction and Objective: Coronavirus disease 2019 (COVID-19) is associated with respiratory failure and a hypercoagulable state. Studies have shown the use of oral anticoagulants, specifically dabigatran, can significantly decrease mortality from COVID-19. Dabigatran is an oral direct thrombin inhibitor commonly used for nonvalvular atrial fibrillation and for the treatment or prevention of venous thromboembolism. The association of COVID-19-related extensive thrombosis while receiving full therapeutic anticoagulation with dabigatran has not been well-established in current literature. Case Report: We present a 73-year-old male patient with a history of persistent atrial fibrillation anticoagulated with dabigatran presenting with an active COVID-19 infection admitted to the intensive care unit. On hospital day 7, he developed extensive arterial and venous thromboembolisms. To our knowledge, this is the first published case of COVID-19-related extensive thrombosis while receiving full therapeutic anticoagulation with dabigatran. Discussion: Guidelines recommend prophylactic or therapeutic-dose anticoagulation with unfractionated heparin or low-molecular weight heparin for all patients if no contraindications exist; however, recommendations for the use of therapeutic oral anticoagulants have not been well established. Further studies are warranted to establish appropriate use of oral anticoagulants in the setting of COVID-19. Conclusion: Evidence from this report suggests clinicians should closely monitor patients at risk for hypercoagulability regardless of the anticoagulation therapy the patient may be receiving. Additionally, evidence from this case suggests a possible inferiority in the anticoagulation ability of dabigatran in patients with active COVID-19.<\/jats:p>","DOI":"10.1177\/00185787221108715","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:57:06Z","timestamp":1656730626000},"page":"774-778","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Coronavirus Disease 2019-Related Extensive Thrombosis in a Patient Receiving Therapeutic Anticoagulation With Dabigatran"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-6163","authenticated-orcid":false,"given":"Robert C.","family":"Ross","sequence":"first","affiliation":[{"name":"North Florida\/South Georgia Veterans Health System, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"North Florida\/South Georgia Veterans Health System, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda P.","family":"Boraas","sequence":"additional","affiliation":[{"name":"North Florida\/South Georgia Veterans Health System, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-8853","authenticated-orcid":false,"given":"Abbie N.","family":"Rosen","sequence":"additional","affiliation":[{"name":"North Florida\/South Georgia Veterans Health System, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-1334","authenticated-orcid":false,"given":"Andrew J.","family":"Franck","sequence":"additional","affiliation":[{"name":"North Florida\/South Georgia Veterans Health System, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"bibr1-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01453-2"},{"key":"bibr2-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100761"},{"key":"bibr3-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2020.100742"},{"key":"bibr4-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02486-4"},{"key":"bibr5-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.11.003"},{"key":"bibr6-00185787221108715","unstructured":"COVID-19 Treatment Guidelines Panel. Information on COVID-19 treatment, prevention and research. National Institutes of Health. Updated: May 31, 2022. Accessed January 24, 2022. https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"key":"bibr7-00185787221108715","unstructured":"Surviving Sepsis Campaign Panel. COVID-19 guidelines. Society of Critical Care Medicine. 2020. Accessed January 24, 2022. https:\/\/sccm.org\/SurvivingSepsisCampaign\/Guidelines\/COVID-19"},{"key":"bibr8-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.6203"},{"key":"bibr9-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105911"},{"key":"bibr10-00185787221108715","unstructured":"Pradaxa (dabigatran etexilate mesylate) [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc.; 2011."},{"key":"bibr11-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001872"},{"key":"bibr12-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020923584"},{"key":"bibr13-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5568982"},{"key":"bibr14-00185787221108715","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020172"},{"key":"bibr15-00185787221108715","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-2-S1-P142"},{"key":"bibr16-00185787221108715","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.50133"},{"key":"bibr17-00185787221108715","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2011.030"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787221108715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787221108715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787221108715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:39:52Z","timestamp":1777451992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787221108715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/00185787221108715"],"URL":"https:\/\/doi.org\/10.1177\/00185787221108715","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}